Ara-290

Ara-290 (cibinetide) is a synthetic 11-amino-acid linear peptide (QEQLERALNSS) derived from helix B of erythropoietin. It was designed to bind the so-called innate repair receptor without activating the erythropoietin receptor that drives red-cell production. It is investigational and not FDA approved.

Cloudiness usually means the peptide has not fully dissolved or has started to aggregate. Common causes are adding diluent too quickly or straight onto the powder, a concentration that is too high, a diluent too cold or at the wrong pH for that peptide, and shaking. Let the vial reach room temperature and swirl gently; some peptides need more time or a different diluent. A solution that stays cloudy, or has particles, should not be used for experiments; contact us with the lot number.

No. Ara-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin and studied in relation to the innate repair receptor. Retatrutide is a 39-amino-acid, fatty-acid-modified agonist of the GIP, GLP-1 and glucagon receptors. They share no sequence, target or developer; the two names simply appear together in some searches.

Published research on Ara-290 (cibinetide) has examined the innate repair receptor, a proposed complex of the erythropoietin receptor and the β-common receptor (CD131), in cell and rodent models of tissue protection, inflammation and nerve injury. It has also been investigated in phase 2 clinical trials in people with sarcoidosis-associated small fiber neuropathy and in people with type 2 diabetes. It was developed by Araim Pharmaceuticals and remains investigational. Findings in cells or animals do not establish effects in people.

No. Ara-290 (cibinetide) is an investigational peptide that has been through early-phase clinical trials but has not been approved by the FDA or any other regulator, and no marketing application for it has been approved anywhere. The material sold here is a research reagent for laboratory use only.

Yes. Ara-290 is a synthetic linear peptide of 11 amino acids (QEQLERALNSS), modeled on the surface of helix B of erythropoietin. It is far smaller than erythropoietin itself, a 165-amino-acid glycoprotein, and carries no sugar chains. It is supplied as a lyophilized powder for laboratory research.

Ara-290 is a polar sequence, rich in charged and hydrophilic residues rather than hydrophobic ones, and it generally dissolves in water-based diluents such as bacteriostatic water, sterile water or a buffered saline such as PBS. Let the sealed vial reach room temperature, add the diluent slowly down the inside wall and swirl gently without shaking. The concentration is the labeled mass divided by the volume added. If the solution stays cloudy or forms a gel, contact us with the lot number.

For storage, yes. Keep lyophilized Ara-290 sealed, dry and refrigerated at 2–8 °C, or frozen at −20 °C for long-term storage, and away from light. The dry powder tolerates room temperature for short periods, such as during shipping. Once reconstituted, keep the solution refrigerated and avoid repeated freeze-thaw cycles.

Erythropoietin (EPO) is a 165-amino-acid glycoprotein hormone that signals through a homodimer of the erythropoietin receptor, the receptor involved in red-blood-cell production. Ara-290 is an 11-amino-acid peptide derived from one helix of EPO and designed to bind the proposed innate repair receptor without activating that homodimer. EPO is an FDA-approved active ingredient; Ara-290 is investigational, and the material sold here is a research reagent.

They are unrelated peptides. Ara-290 is an 11-amino-acid peptide derived from erythropoietin and designed for the proposed innate repair receptor; it has been through phase 2 clinical trials. BPC-157 is a 15-amino-acid peptide based on a protein found in gastric juice, studied mainly in rodent models of nitric oxide and growth-factor signaling. They share no sequence or receptor.

Ara-290 is an 11-amino-acid peptide derived from helix B of erythropoietin and designed for the proposed innate repair receptor. KPV is a three-amino-acid fragment of α-MSH (Lys-Pro-Val) studied in cell and rodent models of inflammation. Both appear in inflammation research, but they come from different parent hormones and act on different targets.

Ara-290 is an 11-amino-acid peptide derived from erythropoietin that targets the proposed innate repair receptor on the cell surface. TB-500 refers to synthetic peptides derived from thymosin β4, a 43-amino-acid protein that binds actin inside cells. They differ in origin, size and target; Ara-290 has been through phase 2 clinical trials, while TB-500 has not been through clinical development.

Ara-290 is an 11-amino-acid peptide derived from erythropoietin and designed for the proposed innate repair receptor. Thymosin alpha-1 is a 28-amino-acid acetylated peptide from prothymosin alpha, studied in immunology. Thymosin alpha-1 is approved as a medicine in some countries outside the U.S.; Ara-290 is investigational everywhere. Neither is FDA approved.

Ara-290: molecular formula C51H87N17O21; molecular weight 1274.4 g/mol. Sequence: QEQLERALNSS. Match these identifiers against the Certificate of Analysis for the lot.

Yes. Each lot has its own Certificate of Analysis, linked on this page for the current lot of each size: 10mg (99.13% HPLC purity). Past certificates are archived in the COA library; contact us with the lot number on the vial label if a certificate is missing.

99.13% (HPLC, current lot). Purity is measured by high-performance liquid chromatography (HPLC) and reported on the lot's Certificate of Analysis.

Ara-290 is supplied as lyophilized powder in a sealed vial: 10mg. In stock and dispatched in 1–2 business days. Quantity pricing applies automatically at 5+ and 10+ vials of the same size.

Store sealed at −20 °C, dry and protected from light.